PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers diseasespecific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.


For the latest news on PDS Biotechnology, please refer to PDS Biotechnology News Center


Therapeutics – Cancer Immunotherapy

Management Team

Frank Bedo-Addo, CEO

Company HQ

North Brunswick, NJ, US



PDS Biotechnology - NetScientific